475561-89-8

Basic information

• Product Name: 1H-Pyrrole-2-carboxylicacid,4-fluoro-,methylester(9CI)
• Synonyms: 1H-Pyrrole-2-carboxylicacid,4-fluoro-,methylester(9CI);Methyl 4-Fluoropyrrole-2-carboxylate;Methyl 4-fluoro-1H-pyrrole-2-carboxylate
• CAS NO: 475561-89-8
• Molecular Formula: C₆H₆FNO₂
• Molecular Weight: 143.12
• Product Categories: CARBOXYLICESTER
• Mol File: 475561-89-8.mol

Chemical Properties

• Melting Point: 94.2-95.4 °C
• Boiling Point: 244.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.302±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.70±0.50(Predicted)
• CAS DataBase Reference: 1H-Pyrrole-2-carboxylicacid,4-fluoro-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole-2-carboxylicacid,4-fluoro-,methylester(9CI)(475561-89-8)
• EPA Substance Registry System: 1H-Pyrrole-2-carboxylicacid,4-fluoro-,methylester(9CI)(475561-89-8)

Safety Data

• Hazardous Substances Data: 475561-89-8(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
1H-Pyrrole-2-carboxylic acid, 4-fluoro-, methyl ester (9CI) is used as a research compound for its potential applications in organic chemistry, pharmaceuticals, and biotechnology. Its reactivity with other substances allows for the exploration of new chemical reactions and the development of novel compounds.
Used in Organic Chemistry:
1H-Pyrrole-2-carboxylic acid, 4-fluoro-, methyl ester (9CI) is used as a synthetic intermediate in the preparation of various organic compounds. Its unique structure and reactivity contribute to the synthesis of complex molecules and the advancement of organic chemistry.
Used in Pharmaceutical Industry:
1H-Pyrrole-2-carboxylic acid, 4-fluoro-, methyl ester (9CI) is used as a building block in the development of new pharmaceutical compounds. Its presence in the molecular structure can influence the properties and effectiveness of potential drug candidates, making it a valuable asset in drug discovery and design.
Used in Biotechnology:
1H-Pyrrole-2-carboxylic acid, 4-fluoro-, methyl ester (9CI) is used in biotechnological applications, such as the development of new bioactive molecules and the study of their interactions with biological systems. Its potential role in the creation of novel biomaterials and the enhancement of existing ones makes it an important compound in the field of biotechnology.

Upstream product

• 362706-26-1 methyl 1-(tert-butoxycarbonyl)-4-oxopyrrolidine-2carboxylate 
• 1000313-00-7 1-(tert-butyl) 2-methyl 4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 915230-14-7 (S)-methyl-4,4-difluoropyrrolidine-2-carboxylate trifluoroacetate 
• 647857-74-7 methyl (R)-1-tert-butoxycarbonyl-4,4-difluoropyrrolidine-2-carboxylate 
• 256487-77-1 (R)-4-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 114676-69-6 (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 915230-15-8 (S)-4,4-difluoro-N-tosyl-pyrrolidine-2-carboxylic acid methyl ester 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 126111-14-6 methyl (2S)-4,4-difluoropyrrolidine-2-carboxylate 

Downstream Products

• 475561-90-1 4-fluoro-pyrrole-2-carboxylic acid 
• 1460286-46-7 1-[2-(4-tert-butyl-phenyl)-2-oxo-ethyl]-4-fluoro-1H-pyrrole-2-carboxylic acid methyl ester 
• 1460285-84-0 3-(4-tert-butyl-phenyl)-7-fluoro-2H-pyrrolo[1,2-a]pyrazin-1-one 

Relevant articles and documents

TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF

Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases.

AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS

Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

PHENYL-3-{ (3- (1H- PYRROL- 2 -YL) - [1 , 2 , 4] 0XADIAZ0L-5-YL] PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention provides new compounds of formula (I) as positive allosteric modulators of metabotropic receptors - subtype 5 ("mGluR5") which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluKi is involved. W represents (C4-C7)cycloalkyl, (C3-C7)heterocycloalkyl , (C3-C7)heterocycloalkyl-(C1-C3)alkyl or (C3-C7)heterocycloalkenyl ring; represents a (C5-C7)heteroeycloalkyl, (C5-C7)heterocycloalkeiiyl ring or a heteroaryl group of formula (a), (b), (c), (d), (e), (f), (g), (i). Q denotes a cycloalkyl, an aryl or heteroaryl group of formula (j), (k), (l), (m), (n). A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR8C(=O)-, -NR8C(=O)-O-, -NR8C(=O)-NR9, NR8S(=O)2-, -C(=O)NR8-, -O-C(=O)NR8-, -S-, -S(=O)-, -S(=O)2-, -S(C=O)2NR8-, -C(=0)-0-, -0-C(=0)-, -C(=NR8)NR9-, C(C=NOR8)NR9- , -NR8C(=NOR9)-, =N-0-, -0-N=CH- or a group aryl or heteroaryl of formula, (o), (p), (q), (r), (s), (t), (u), (v), (w), (x). The other substituents are defined in the claims.

Synthesis and characterization of partially β-fluorinated 5,10,15,20-tetraphenylporphyrins and some derivatives

The synthesis of partially β-fluorinated meso-tetraphenylporphyrins using Lindsey conditions, has been examined, starting either from 3,4-difluoro-1H-pyrrole or from 3-fluoro-1H-pyrrole. In the case of the first synthon, condensation with pyrrole and benzaldehyde afforded a mixture of porphyrins of general formula β-FnTPP (n=0,2,4,6,8) displaying linearly correlated spectroscopic and electrochemical properties. With the second synthon, condensation with benzaldehyde produced an unresolvable mixture of β-tetrafluoroporphyrins presenting spectroscopic and electrochemical properties in coherence with those observed in the first case. Preliminarily, the synthesis and isolation of the hitherto unknown 3-fluoro-1H-pyrrole has been approached via several methods.